|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogel RI, Pulver T, Heilmann W, Mooneyham
A, Mullany S, Zhao X, Shahi M, Richter J, Klein M, Chen L, et al:
USP14 is a predictor of recurrence in endometrial cancer and a
molecular target for endometrial cancer treatment. Oncotarget.
7:30962–30976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tran AQ and Gehrig P: Recent advances in
endometrial cancer. F1000Res. 6:812017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang S, Kang WD, Chung HH, Jeong DH, Seo
SS, Lee JM, Lee JK, Kim JW, Kim SM, Park SY and Kim KT:
Preoperative identification of a low-risk group for lymph node
metastasis in endometrial cancer: A Korean gynecologic oncology
group study. J Clin Oncol. 30:1329–1334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wright JD, Burke WM, Wilde ET, Lewin SN,
Charles AS, Kim JH, Goldman N, Neugut AI, Herzog TJ and Hershman
DL: Comparative effectiveness of robotic versus laparoscopic
hysterectomy for endometrial cancer. J Clin Oncol. 30:783–791.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brasseur K, Gévry N and Asselin E:
Chemoresistance and targeted therapies in ovarian and endometrial
cancers. Oncotarget. 8:4008–4042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakamura K, Sawada K, Yoshimura A, Kinose
Y, Nakatsuka E and Kimura T: Clinical relevance of circulating
cell-free microRNAs in ovarian cancer. Mol Cancer. 15:482016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot
CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated
analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell.
23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Y, Wang M, Wu J, Jie Z, Chang S and
Shuang T: The clinicopathological significance of miR-1307 in
chemotherapy resistant epithelial ovarian cancer. J Ovarian Res.
8:232015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Záveský L, Jandáková E, Turyna R,
Langmeierová L, Weinberger V, Záveská Drábková L, Hůlková M,
Hořínek A, Dušková D, Feyereisl J, et al: Evaluation of cell-free
urine microRNAs expression for the use in diagnosis of ovarian and
endometrial cancers. A pilot study. Pathol Oncol Res. 21:1027–1035.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ran X, Yang J, Liu C, Zhou P, Xiao L and
Zhang K: miR-218 inhibits HMGB1-mediated autophagy in endometrial
carcinoma cells during chemotherapy. Int J Clin Exp Pathol.
8:6617–6626. 2015.PubMed/NCBI
|
|
13
|
Dong P, Kaneuchi M, Watari H, Hamada J,
Sudo S, Ju J and Sakuragi N: MicroRNA-194 inhibits epithelial to
mesenchymal transition of endometrial cancer cells by targeting
oncogene BMI-1. Mol Cancer. 10:992011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu P, Wang C, Ma C, Wu Q, Zhang W and Lao
G: MicroRNA-23a regulates epithelial-to-mesenchymal transition in
endometrial endometrioid adenocarcinoma by targeting SMAD3. Cancer
Cell Int. 16:672016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Li X, Liao D, Wang X, Wu Z, Nie J,
Bai M, Fu X, Mei Q and Han W: Elevated microRNA-23a expression
enhances the chemo-resistance of colorectal cancer cells with
microsatellite instability to 5-fluorouracil by directly targeting
ABCF1. Curr Protein Pept Sci. 16:301–309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guan L, Hu X, Liu L, Xing Y, Zhou Z, Liang
X, Yang Q, Jin S, Bao J, Gao H, et al: Bta-miR-23a involves in
adipogenesis of progenitor cells derived from fetal bovine skeletal
muscle. Sci Rep. 7:437162017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Wang Y, Liang H, Fan Q, Zhu R, Cui
J, Zhang W, Zen K, Zhang CY, Hou D, et al: miR-23a/b promote tumor
growth and suppress apoptosis by targeting PDCD4 in gastric cancer.
Cell Death Dis. 8:e30592017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shang J, Yang F, Wang Y, Wang Y, Xue G,
Mei Q, Wang F and Sun S: MicroRNA-23a antisense enhances
5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic
pathway in colorectal cancer cells. J Cell Biochem. 115:772–784.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun KX, Jiao JW, Chen S, Liu BL and Zhao
Y: MicroRNA-186 induces sensitivity of ovarian cancer cells to
paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res.
8:802015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Z, Li G, Tang L and Li Y: SIX1
overexpression predicts poor prognosis and induces radioresistance
through AKT signaling in esophageal squamous cell carcinoma. Onco
Targets Ther. 10:1071–1079. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xin X, Li Y and Yang X: SIX1 is
overexpressed in endometrial carcinoma and promotes the malignant
behavior of cancer cells through ERK and AKT signaling. Oncol Lett.
12:3435–3440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawasaki T, Takahashi M, Yajima H, Mori Y
and Kawakami K: Six1 is required for mouse dental follicle cell and
human periodontal ligament-derived cell proliferation. Dev Growth
Differ. 58:530–545. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L and Liu H: microRNA-188 is
downregulated in oral squamous cell carcinoma and inhibits
proliferation and invasion by targeting SIX1. Tumour Biol.
37:4105–4113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu D, Li L, Zhang XX, Wan DY, Xi BX, Hu
Z, Ding WC, Zhu D, Wang XL, Wang W, et al: SIX1 promotes tumor
lymphangiogenesis by coordinating TGFβ signals that increase
expression of VEGF-C. Cancer Res. 74:5597–5607. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng GW, Dong LD, Shang WJ, Pang XL, Li
JF, Liu L and Wang Y: HDAC5 promotes cell proliferation in human
hepatocellular carcinoma by up-regulating Six1 expression. Eur Rev
Med Pharmacol Sci. 18:811–816. 2014.PubMed/NCBI
|
|
27
|
Li Z, Tian T, Hu X, Zhang X, Nan F, Chang
Y, Lv F and Zhang M: Six1 mediates resistance to paclitaxel in
breast cancer cells. Biochem Biophys Res Commun. 441:538–543. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hetzler KL, Collins BC, Shanely RA, Sue H
and Kostek MC: The homoeobox gene SIX1 alters myosin heavy chain
isoform expression in mouse skeletal muscle. Acta Physiol (Oxf).
210:415–428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garcez RC, Le Douarin NM and Creuzet SE:
Combinatorial activity of Six1-2-4 genes in cephalic neural crest
cells controls craniofacial and brain development. Cell Mol Life
Sci. 71:2149–2164. 2014.PubMed/NCBI
|
|
30
|
Li Z, Tian T, Lv F, Chang Y, Wang X, Zhang
L, Li X, Li L, Ma W, Wu J and Zhang M: Six1 promotes proliferation
of pancreatic cancer cells via upregulation of cyclin D1
expression. PLoS One. 8:e592032013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato S, Ikeda K, Shioi G, Ochi H, Ogino H,
Yajima H and Kawakami K: Conserved expression of mouse Six1 in the
pre-placodal region (PPR) and identification of an enhancer for the
rostral PPR. Dev Biol. 344:158–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ng KT, Lee TK, Cheng Q, Wo JY, Sun CK, Guo
DY, Lim ZX, Lo CM, Poon RT, Fan ST and Man K: Suppression of
tumorigenesis and metastasis of hepatocellular carcinoma by shRNA
interference targeting on homeoprotein Six1. Int J Cancer.
127:859–872. 2010.PubMed/NCBI
|
|
33
|
Plant KE, Anderson E, Simecek N, Brown R,
Forster S, Spinks J, Toms N, Gibson GG, Lyon J and Plant N: The
neuroprotective action of the mood stabilizing drugs lithium
chloride and sodium valproate is mediated through the up-regulation
of the homeodomain protein Six1. Toxicol Appl Pharmacol.
235:124–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu Y, Davicioni E, Triche TJ and Merlino
G: The homeoprotein six1 transcriptionally activates multiple
protumorigenic genes but requires ezrin to promote metastasis.
Cancer Res. 66:1982–1989. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Coletta RD, Christensen K, Reichenberger
KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, Müller-Tidow C, Golub
TR, Kawakami K and Ford HL: The Six1 homeoprotein stimulates
tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci USA.
101:6478–6483. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reichenberger KJ, Coletta RD, Schulte AP,
Varella-Garcia M and Ford HL: Gene amplification is a mechanism of
Six1 overexpression in breast cancer. Cancer Res. 65:2668–2675.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng XH, Liang PH, Guo JX, Zheng YR, Han
J, Yu LL, Zhou YG and Li L: Expression and clinical implications of
homeobox gene Six1 in cervical cancer cell lines and cervical
epithelial tissues. Int J Gynecol Cancer. 20:1587–1592.
2010.PubMed/NCBI
|
|
38
|
Behbakht K, Qamar L, Aldridge CS, Coletta
RD, Davidson SA, Thorburn A and Ford HL: Six1 overexpression in
ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and
is associated with poor survival. Cancer Res. 67:3036–3042. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smith AL, Iwanaga R, Drasin DJ, Micalizzi
DS, Vartuli RL, Tan AC and Ford HL: The miR-106b-25 cluster targets
Smad7, activates TGF-b signaling, and induces EMT and tumor
initiating cell characteristics downstream of Six1 in human breast
cancer. Oncogene. 31:5162–5171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Radisky DC: Defining a role for the
homeoprotein Six1 in EMT and mammary tumorigenesis. J Clin Invest.
119:2528–2531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ono H, Imoto I, Kozaki K, Tsuda H, Matsui
T, Kurasawa Y, Muramatsu T, Sugihara K and Inazawa J: SIX1 promotes
epithelial-mesenchymal transition in colorectal cancer through ZEB1
activation. Oncogene. 31:4923–4934. 2012. View Article : Google Scholar : PubMed/NCBI
|
